AlzeCure Pharma
Stage
IPO | IPODate of IPO
11/28/2018About AlzeCure Pharma
AlzeCure Pharma is a Swedish pharmaceutical company with a primary focus on Alzheimer's disease. The company is developing five drug candidates within its two main research programs, NeuroRestore och Alzstatin.
Missing: AlzeCure Pharma's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: AlzeCure Pharma's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing AlzeCure Pharma
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
AlzeCure Pharma is included in 1 Expert Collection, including Biopharma Tech.
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
AlzeCure Pharma Patents
AlzeCure Pharma has filed 6 patents.
The 3 most popular patent topics include:
- Growth factors
- Experimental cancer drugs
- Neurotrophic factors
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
2/26/2019 | 6/7/2022 | Tyrosine kinase receptors, Transcription factors, Proteins, Growth factors, Developmental neuroscience | Grant |
Application Date | 2/26/2019 |
|---|---|
Grant Date | 6/7/2022 |
Title | |
Related Topics | Tyrosine kinase receptors, Transcription factors, Proteins, Growth factors, Developmental neuroscience |
Status | Grant |
Latest AlzeCure Pharma News
Feb 25, 2023
ACD-440 is under clinical development by AlzeCure Pharma and currently in Phase I for Neuropathic Pain (Neuralgia). According to GlobalData, Phase I drugs for Neuropathic Pain (Neuralgia) have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ACD-440’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. ACD-440 overview ACD-440 is under development for the treatment of neuropathic pain including painful peripheral polyneuropathy, peripheral mononeuropathy, postherpetic neuralgia (PHN), chemotherapy induced neuropathic pain, nerve injury pain, chronic postoperative neuropathic pain and peripheral neuropathic pain. It is administered via cutaneous route. The drug candidate acts by targeting vanilloid receptor 1. AlzeCure Pharma overview AlzeCure Pharma (AlzeCure) is a drug discovery company that develops therapies for the treatment of age related diseases. The company offers diagnostics and medical technologies for the treatment of alzheimer’s disease and others neurodegenerative conditions. It develops ongoing proprietary research projects through preclinical discovery into clinical phase. AlzeCure has identified drug-like small molecule compounds, affecting the trophic signaling pathways. The company will develop and conduct resesarch of its projects to early clinical phase and try to find suitable out-licensing solutions with other pharmaceutical companies for its products. Alzecure is developing several parallel drug candidates based on the three research platforms : NeuroRestore, Alzstatin and Painless. The company works in collaboration with various companies to develop proprietary research projects. AlzeCure is headquartered in Huddinge, Sweden. For a complete picture of ACD-440’s drug-specific PTSR and LoA scores, buy the report here. Share this article
AlzeCure Pharma Frequently Asked Questions (FAQ)
Where is AlzeCure Pharma's headquarters?
AlzeCure Pharma's headquarters is located at Hälsovägen 7, Huddinge.
What is AlzeCure Pharma's latest funding round?
AlzeCure Pharma's latest funding round is IPO.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.